Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab with cisplatin and pemetrexed in stage IV lung adenocarcinoma
NCT02120807Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2014
- Primary completion
- Jan 2023
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of certolizumab pegol in lung adenocarcinoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Apr 2014; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02120807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120807.